Medical management of variceal bleeding in patients with cirrhosis

Canadian Journal of Gastroenterology

Volumn 18, Issue 2, 2004, Pages 109-113

  Abraldes, Juan G ^a   Dell'Era, Alessandra ^a   Bosch, Jaime ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Medical therapy; Variceal bleeding; Vasoactive drugs

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BLOOD CLOTTING FACTOR 7; GLYCERYL TRINITRATE; NORFLOXACIN; OCTREOTIDE; PLACEBO; SCLEROSING AGENT; SOMATOSTATIN; TERLIPRESSIN; VASOACTIVE AGENT; VASOPRESSIN;

ARTICLE; BLOOD TRANSFUSION; BLOOD VESSEL COMPLIANCE; BLOOD VESSEL WALL; CARDIOVASCULAR DISEASE; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; ENDOSCOPIC SCLEROTHERAPY; ENDOSCOPIC THERAPY; ESOPHAGUS VARICES BLEEDING; FLUID THERAPY; HEALTH CARE PERSONNEL; HEMATOCRIT; HOSPITAL ADMISSION; HUMAN; INFECTION; LIVER CIRCULATION; LIVER CIRRHOSIS; MEDICAL DECISION MAKING; MORTALITY; PARAMEDICAL PERSONNEL; PATHOPHYSIOLOGY; PATIENT TRANSPORT; PORTAL VEIN BLOOD PRESSURE; PORTOSYSTEMIC ANASTOMOSIS; PRIORITY JOURNAL; SURVIVAL; TREATMENT FAILURE; VASCULAR RESISTANCE; VASODILATATION; VEIN LIGATION;

EID: 1842526567     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/2004/560215     Document Type: Article

References (49)

1. Cardenas A, Gines P, Uriz J, et al. Renal failure after upper gastrointestinal bleeding in cirrhosis: Incidence, clinical course, predictive factors, and short-term prognosis. Hepatology 2001;34:671-6.
2. D'Amico G, Luca A. Natural history. Clinical-haemodynamic correlations. Prediction of the risk of bleeding. Baillieres Clin Gastroenterol 1997;11:243-56.
3. De Franchis R, Primignani M. Natural history of portal hypertension in patients with cirrhosis. Clin Liver Dis 2001;5:645-63.
4. Ben-Ari Z, Cardin F, McCormick AP, Wannamethee G, Burroughs AK. A predictive model for failure to control bleeding during acute variceal haemorrhage. J Hepatol 1999;31:443-50.
5. Goulis J, Armonis A, Patch D, Sabin C, Greenslade L, Burroughs AK. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology 1998;27:1207-12.
6. Moitinho E, Escorsell A, Bandi JC, et al. Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology 1999;117:626-31.
7. Graham DY, Smith JL. The course of patients after variceal hemorrhage. Gastroenterology 1981;80:800-9.
8. D'Amico G, De Franchis R. Cooperative Study Group. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 2003;38:599-612.
9. McCormick PA, O'Keefe C. Improving prognosis following a first variceal haemorrhage over four decades. Gut 2001;49:682-5.
10. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: An evidence-based approach. Semin Liver Dis 1999;19:475-505.
11. Wiest R, Groszmann RJ. Nitric oxide and portal hypertension: Its role in the regulation of intrahepatic and splanchnic vascular resistance. Semin Liver Dis 1999;19:411-26.
12. Bosch J, Garcia-Pagan JC. Complications of cirrhosis. I. Portal hypertension. J Hepatol 2000;31(Suppl 1):141-56.
13. Viallet A, Marleau D, Huet M, et al. Hemodynamic evaluation of patients with intrahepatic portal hypertension. Relationship between bleeding varices and the portohepatic gradient. Gastroenterology 1975;69:1297-300.
14. Garcia-Tsao G, Groszmann RJ, Fisher RL, Conn HO, Atterbury CE, Glickman M. Portal pressure, presence of gastroesophageal varices and variceal bleeding. Hepatology 1985;5:419-24.
15. Groszmann RJ, Bosch J, Grace ND, et al. Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology 1990;99:1401-7.
16. Feu F, Garcia-Pagan JC, Bosch J, et al. Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet 1995;346:1056-9.
17. Polio J, Groszmann RJ. Hemodynamic factors involved in the development and rupture of esophageal varices: A pathophysiologic approach to treatment. Semin Liver Dis 1986;6:318-31.
18. Castaneda B, Debernardi-Venon W, Bandi JC, et al. The role of portal pressure in the severity of bleeding in portal hypertensive rats. Hepatology 2000;31:581-6.
19. McCormick PA, Jenkins SA, McIntyre N, Burroughs AK. Why portal hypertensive varices bleed and bleed: A hypothesis. Gut 1995;36:100-3.
20. Bernard B, Grange JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: A meta-analysis. Hepatology 1999;29:1655-61.
21. Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: A consensus document. International Ascites Club. J Hepatol 2000;32:142-53.
22. Bernstein DE, Jeffers L, Erhardtsen E, et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: A preliminary study. Gastroenterology 1997;113:1930-7.
23. Ejlersen E, Melsen T, Ingerslev J, Andreasen RB, Vilstrup H. Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices. Scand J Gastroenterol 2001;36:1081-5.
24. Thabut D, de Franchis R, Bendtsen F, et al. Efficacy of activated recombinant factor VII (rFVIIa; Novoseven) in cirrhotic patients with upper gastrointestinal bleeding: A randomized placebo-controlled double-blind multicenter trial. J Hepatol 2003;38(Suppl 2):13A. (Abst)
25. De Franchis R, Primignani M. Endoscopic treatments for portal hypertension. Semin Liver Dis 1999;19:439-55.
26. Burroughs AK, Patch D. Transjugular intrahepatic portosystemic shunt. Semin Liver Dis 1999;19:457-73.
27. Levacher S, Letoumelin P, Pateron D, Blaise M, Lapandry C, Pourriat JL. Early administration of terlipressin plus glyceryl trinitrate to control active upper gastrointestinal bleeding in cirrhotic patients. Lancet 1995;346:865-8.
28. Abraldes JG, Bosch J. Somatostatin and analogues in portal hypertension. Hepatology 2002;35:1305-12.
29. Bosch J, Lebrec D, Jenkins SA. Development of analogues: Successes and failures. Scand J Gastroenterol 1998;33(Suppl 226):3-13.
30. Escorsell A, Ruiz del Arbol L, Planas R, et al. Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: The TEST study. Hepatology 2000;32:471-6.
31. Ioannou GN, Doust J, Rockey DC. Systematic review: Terlipressin in acute oesophageal variceal haemorrhage. Aliment Pharmacol Ther 2003;17:53-64.
32. Tyden G, Sammegard H, Thulin L, Friman L, Efendic S. Treatment of bleeding esophageal varices with somatostatin. N Engl J Med 1978;299:1466-7. (Lett)
33. Bosch J, Kravetz D, Rodes J. Effects of somatostatin on hepatic and systemic hemodynamics in patients with cirrhosis of the liver: Comparison with vasopressin. Gastroenterology 1981;80:518-25.
34. Escorsell A, Bordas JM, del Arbol LR, et al. Randomized controlled trial of sclerotherapy versus somatostatin infusion in the prevention of early rebleeding following acute variceal hemorrhage in patients with cirrhosis. Variceal Bleeding Study Group. J Hepatol 1998;29:779-88.
35. Moitinho E, Planas R, Bañares R, et al. Variceal Bleeding Study Group. Multicenter randomized controlled trial comparing different schedules of somatostatin in the treatment of acute variceal bleeding. J Hepatol 2001;35:712-8.
36. Escorsell A, Bandi JC, Andreu V, et al. Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology 2001;120:161-9.
37. Burroughs AK. International Octreotide Study Group. Double-blind RCT of 5 day octreotide versus placebo, associated with sclerotherapy for trial failures. Hepatology 1996;24:352A. (Abst)
38. Corley DA, Cello JP, Adkisson W, Ko WF, Kerlikowske K. Octreotide for acute esophageal variceal bleeding: A meta-analysis. Gastroenterology 2001;120:946-54.
39. De Franchis R. Updating consensus in portal hypertension: Report of the Baveno III Consensus Workshop on definitions, methodology and therapeutic strategies in portal hypertension. J Hepatol 2000;33:846-52.
40. Burroughs AK, Patch DW. Management of variceal haemorrhage in cirrhotic patients. Gut 2001;48:738-40. (Lett)
41. Avgerinos A, Nevens F, Raptis S, Fevery J. Early administration of somatostatin and efficacy of sclerotherapy in acute oesophageal variceal bleeds: The European Acute Bleeding Oesophageal Variceal Episodes (ABOVE) randomised trial. Lancet 1997;350:1495-9.
42. Cales P, Masliah C, Bernard B, et al. French Club for the Study of Portal Hypertension. Early administration of vapreotide for variceal bleeding in patients with cirrhosis. French Club for the Study of Portal Hypertension. N Engl J Med 2001;344:23-8.
43. Villanueva C, Ortiz J, Sabat M, et al. Somatostatin alone or combined with emergency sclerotherapy in the treatment of acute esophageal variceal bleeding: A prospective randomized trial. Hepatology 1999;30:384-9.
44. Bañares R, Albillos A, Rincon D, et al. Endoscopic treatment versus endoscopic plus pharmacologic treatment for acute variceal bleeding: A meta-analysis. Hepatology 2002;35:609-15.
45. D'Amico G, Pietrosi G, Tarantino I, Pagliaro L. Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: A Cochrane meta-analysis. Gastroenterology 2003;124:1277-91.
46. Bosch J, Abraldes JG, Groszmann R. Current management of portal hypertension. J Hepatol 2003;38(Suppl 1):S54-68.
47. D'Amico G, Pagliaro L, Bosch J. The treatment of portal hypertension: A meta-analytic review. Hepatology 1995;22:332-54.
48. Bosch J. Salvage transjugular intrahepatic portosystemic shunt: Is it really life-saving? J Hepatol 2001;35:658-60.
49. Henderson JM. Salvage therapies for refractory variceal hemorrhage. Clin Liver Dis 2001;5:709-25.